This section covers biotechnology in the United States — gene editing, genomics, drug development and the research and business developments shaping the sector. Reporting takes in both the science and the commercial activity around it.
Latus Bio researchers report that lowering MSH3 protein levels in brain cells slowed disease progression in preclinical models.
Live Poll
Should the government fund gene therapy research for inherited diseases like Huntington's?
November 7, 2026
10x Genomics Raises 2026 Revenue OutlookThe life sciences company now expects $625 million to $635 million in 2026 revenue, up from its previous range, as spatial biology demand grows.
November 7, 2026
Arcturus Narrows Q3 Loss to $7.4 MillionThe clinical-stage biotech reported revenue growth driven by a one-time termination payment tied to the end of its CSL Seqirus collaboration.
November 6, 2026
Iovance Revenue Rises 80% on Amtagvi DemandIovance Biotherapeutics reported record third-quarter 2026 revenue and a narrower net loss versus the year-earlier period.
November 6, 2026
Colossal Sues Ex-Executive Over Trade SecretsColossal Biosciences alleges former senior executive James Kehler took confidential information before joining a competing start-up.
November 6, 2026
BriaCell Shows Immunotherapy Data at SITC 2026Four preclinical posters from BriaCell and BriaPro highlight new immunotherapy platform and checkpoint-modulating candidates at the annual meeting in Phoenix.
November 6, 2026
PacBio Narrows 2026 Revenue Guidance to $155M-$160MThe genomics company reiterated its 2028 cash-flow breakeven target while lowering its operating expense outlook.
November 6, 2026
NIH Proposes Safety-Monitoring Policy OverhaulThe National Institutes of Health released a draft policy requiring approved safety-monitoring plans for all NIH-supported clinical research, with public comments accepted until January 6, 2027.
November 5, 2026
Vir Biotechnology Reports $96.3 Million Q3 LossThe biotech posted a narrower third-quarter loss than a year earlier as research spending fell and cash reserves remained above $900 million.
November 5, 2026
Larimar Presents Nomlabofusp Data at Ataxia CongressLarimar Therapeutics will present three poster presentations on nomlabofusp at the International Congress for Ataxia Research 2026 in Atlanta.
November 5, 2026
IN8bio Reports $4.6 Million Q3 Net LossThe biotech company posted a wider quarterly loss than a year earlier as research spending rose and it added a new research leader.
Coverage takes in clinical trial results, regulatory submissions and decisions, genomics research findings, gene therapy developments, acquisitions and the funding rounds that signal where the sector is placing its bets. New York, Los Angeles, Chicago, Houston and Phoenix are significant hubs for biotech investment and commercialization, and transactions and company news from those markets feature consistently. The distance between a research finding and a commercial product is long in this sector, and coverage of that gap — through trials, regulatory review and manufacturing scale-up — forms a durable part of the reporting calendar. Acquisition activity has been a reliable source of coverage as larger pharmaceutical companies acquire biotech firms that have moved a therapy through early clinical stages.
